Ann Knoop

4.6k total citations
116 papers, 2.7k citations indexed

About

Ann Knoop is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ann Knoop has authored 116 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 70 papers in Cancer Research and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ann Knoop's work include Breast Cancer Treatment Studies (56 papers), HER2/EGFR in Cancer Research (49 papers) and Cancer Treatment and Pharmacology (30 papers). Ann Knoop is often cited by papers focused on Breast Cancer Treatment Studies (56 papers), HER2/EGFR in Cancer Research (49 papers) and Cancer Treatment and Pharmacology (30 papers). Ann Knoop collaborates with scholars based in Denmark, United States and Switzerland. Ann Knoop's co-authors include Marianne Ewertz, Bent Ejlertsen, Anne‐Vibeke Lænkholm, Birgitte Rasmussen, Maj‐Britt Jensen, Lise Eckhoff, Jeanette Dupont Jensen, Kirsten Vang Nielsen, Jens Overgaard and Eva Balslev and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ann Knoop

105 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Knoop Denmark 27 1.8k 1.3k 912 517 391 116 2.7k
Henrik Lindman Sweden 27 1.9k 1.1× 1.0k 0.8× 522 0.6× 487 0.9× 967 2.5× 121 3.1k
Kenjiro Aogi Japan 28 1.7k 1.0× 818 0.6× 521 0.6× 573 1.1× 434 1.1× 150 2.9k
Carla I. Falkson United States 26 1.8k 1.1× 797 0.6× 811 0.9× 528 1.0× 316 0.8× 95 2.8k
Laura Orlando Italy 27 1.9k 1.1× 1.3k 1.0× 946 1.0× 543 1.1× 186 0.5× 92 2.9k
Günther Steger Austria 27 1.6k 0.9× 660 0.5× 485 0.5× 424 0.8× 411 1.1× 69 2.2k
Toshinari Yamashita Japan 24 1.9k 1.1× 1.1k 0.9× 1.3k 1.4× 1.6k 3.0× 211 0.5× 135 3.7k
William M. Sikov United States 26 2.3k 1.3× 1.7k 1.3× 590 0.6× 660 1.3× 412 1.1× 93 3.4k
B. Ojeda Spain 26 1.9k 1.1× 1.1k 0.8× 380 0.4× 388 0.8× 697 1.8× 57 2.8k
Li‐E Wang United States 37 1.1k 0.6× 910 0.7× 2.2k 2.4× 537 1.0× 461 1.2× 88 3.4k
G. Deplanque France 23 1.3k 0.7× 542 0.4× 633 0.7× 812 1.6× 221 0.6× 77 2.3k

Countries citing papers authored by Ann Knoop

Since Specialization
Citations

This map shows the geographic impact of Ann Knoop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Knoop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Knoop more than expected).

Fields of papers citing papers by Ann Knoop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Knoop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Knoop. The network helps show where Ann Knoop may publish in the future.

Co-authorship network of co-authors of Ann Knoop

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Knoop. A scholar is included among the top collaborators of Ann Knoop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Knoop. Ann Knoop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berg, Tobias, Lise Barlebo Ahlborn, Maj‐Britt Jensen, et al.. (2025). Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer. Neoplasia. 63. 101162–101162.
2.
Kastora, Stavroula, Eirini Pantiora, Hatem A. Azim, et al.. (2025). Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion. Cancer Treatment Reviews. 133. 102880–102880. 3 indexed citations
3.
Berg, Tobias, Maj‐Britt Jensen, Maria Rossing, et al.. (2024). Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer. JAMA Network Open. 7(3). e242174–e242174. 4 indexed citations
4.
Jensen, Maj‐Britt, Eva Balslev, Ann Knoop, et al.. (2024). Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial. Journal of Clinical Oncology. 43(4). 373–380. 3 indexed citations
5.
Knoop, Ann, et al.. (2024). Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer. SHILAP Revista de lepidopterología. 2(1). 82–82. 5 indexed citations
6.
Jensen, Maj‐Britt, et al.. (2024). Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer. SHILAP Revista de lepidopterología. 2(1). 44–44. 8 indexed citations
7.
Berg, Tobias, Maj‐Britt Jensen, Maj‐Lis Talman, et al.. (2024). Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study. JCI Insight. 9(7). 3 indexed citations
8.
Knoop, Ann, et al.. (2023). Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world patients.. PubMed. 70(9).
9.
Berg, Tobias, et al.. (2023). Real-world survival of Danish patients with HER2-positive metastatic breast cancer. Acta Oncologica. 62(6). 601–607.
10.
Nielsen, Dorte, Erik Jakobsen, Sven Tyge Langkjer, et al.. (2023). Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 3130–3130.
11.
12.
Mejdahl, Mathias Kvist, et al.. (2022). Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study. Breast Cancer Research and Treatment. 198(1). 103–112.
13.
Jørgensen, Jan Trøst, Susanne Möller, Birgitte Rasmussen, et al.. (2011). High Concordance Between Two Companion Diagnostics Tests. American Journal of Clinical Pathology. 136(1). 145–151. 17 indexed citations
14.
Jensen, Jeanette Dupont, Ann Knoop, Marianne Ewertz, & Anne‐Vibeke Lænkholm. (2011). ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Research and Treatment. 132(2). 511–521. 53 indexed citations
15.
Jensen, Jeanette Dupont, Anne‐Vibeke Lænkholm, Ann Knoop, et al.. (2010). PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer. Clinical Cancer Research. 17(4). 667–677. 151 indexed citations
16.
Damkier, Anette, Christine Paludan-Müller, & Ann Knoop. (2007). [Use of complementary and alternative medicine (CAM) in breast cancer patients. Efficacy and interactions].. PubMed. 169(37). 3111–4. 2 indexed citations
17.
Hildebrandt, Malene Grubbe, Peter Bartram, Martin Bak, et al.. (2005). Low risk of recurrence in breast cancer with negative sentinel node.. University of Southern Denmark Research Portal (University of Southern Denmark). 58(31). 120–127. 4 indexed citations
18.
19.
Knoop, Ann, P.A. Andreasen, Steinbjørn Hansen, et al.. (1998). Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. British Journal of Cancer. 77(6). 932–940. 88 indexed citations
20.
Gerdes, Anne‐Marie, Ole Nielsen, Per Pfeiffer, et al.. (1998). Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2.. PubMed. 18(4A). 2529–34. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Henrik Lindman Breakdown of academic impact, for papers by Kenjiro Aogi Breakdown of academic impact, for papers by Carla I. Falkson Breakdown of academic impact, for papers by Laura Orlando Breakdown of academic impact, for papers by Günther Steger Breakdown of academic impact, for papers by Toshinari Yamashita Breakdown of academic impact, for papers by William M. Sikov Breakdown of academic impact, for papers by B. Ojeda Breakdown of academic impact, for papers by Li‐E Wang Breakdown of academic impact, for papers by G. Deplanque
Rankless by CCL
2026